Physician profile
Bobby Chawla
NPI 1598956963
$1,034,506.21
in general payments reported to CMS, 2019-2025
67 companies · $207K in 2025
The $207K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $14K · 2021: $38K · 2022: $151K · 2023: $256K · 2024: $290K · 2025: $207K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $548K · Travel and Lodging: $91K · Consulting Fee: $67K · Food and Beverage: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $18K · Honoraria: $5,435 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $547,785.00 |
| Travel and Lodging | $91,221.33 |
| Consulting Fee | $67,263.25 |
| Food and Beverage | $23,291.48 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,719.44 |
| Honoraria | $5,435.00 |
| Education | $484.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $298,813.25 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $211,036.20 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Incyte Corporation | $172,450.69 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $63,324.77 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| Amgen INC. | $42,266.59 | 2019-2025 | Imdelltra (Amg757), Imdelltra (Amg 757), Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $41,908.26 | 2020-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Sobi, INC | $37,858.20 | 2024 | |
| Cti Biopharma Corp. | $22,549.20 | 2023 | Vonjo |
| Tempus Ai, INC | $21,507.81 | 2024-2025 | Xt Cdx, Tempus Pixel |
| Bayer Healthcare Pharmaceuticals INC. | $20,125.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19,495.87 | 2019-2025 | Gilotrif |
| Emd Serono, INC. | $17,967.27 | 2019-2025 | Bavencio |
| Eisai INC. | $12,032.63 | 2019-2024 | |
| Daiichi Sankyo INC. | $10,478.21 | 2019-2025 | Datroway, Enhertu |
| Exelixis INC. | $7,994.57 | 2019-2025 | Cabometyx |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $5,652.65 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Kite Pharma, INC. | $5,549.07 | 2022-2025 | Yescarta |
| Janssen Biotech, INC. | $4,839.63 | 2019-2025 | Imbruvica, Erleada, Akeega |
| Pharmaessentia USA Corporation | $2,701.07 | 2024-2025 | Besremi |
| Abbvie INC. | $2,508.85 | 2019-2025 | Venclexta |
| Bristol Myers Squibb Company | $2,372.00 | 2023 | |
| Seagen INC. | $1,381.30 | 2020-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $1,204.57 | 2019-2025 | |
| Macrogenics, INC. | $1,200.00 | 2022 | |
| Beigene USA, INC. | $1,137.04 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $670.95 | 2023-2025 | Libtayo |
| Myriad Genetic Laboratories, INC. | $526.24 | 2023-2024 | Myrisk |
| Beigene, Ltd. | $525.00 | 2021 | |
| Genentech USA, INC. | $516.64 | 2019-2025 | Phesgo, Perjeta, Tecentriq |
| Pfizer INC. | $434.45 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $360.73 | 2019-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $358.20 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $352.56 | 2019-2025 | Padcev, Xospata, Vyloy |
| Jazz Pharmaceuticals INC. | $260.78 | 2024-2025 | |
| Genzyme Corporation | $222.31 | 2020-2025 | |
| Blueprint Medicines Corporation | $203.63 | 2020-2025 | Ayvakit |
| Adaptive Biotechnologies Corporation | $171.27 | 2023-2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $166.67 | 2024-2025 | Orgovyx |
| Genmab U.S., INC. | $165.15 | 2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $129.09 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Geron Corporation | $123.82 | 2025 | Rytelo |
| Array Biopharma INC | $105.48 | 2023-2025 | Xalkori, Lorbrena, Mektovi |
| Novocure INC. | $102.40 | 2025 | Optune Lua (Novottf-200t) |
| Lilly USA, LLC | $87.22 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Alexion Pharmaceuticals, INC. | $86.43 | 2019-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $57.01 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $54.43 | 2019 | |
| Stemline Therapeutics INC. | $48.64 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $41.39 | 2019-2021 | |
| Gilead Sciences, INC. | $37.89 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $35.00 | 2024-2025 | |
| Kyowa Kirin, INC. | $33.60 | 2024 | Poteligeo |
| Morphosys, US INC. | $31.54 | 2023 | Monjuvi |
| Foundation Medicine, INC. | $26.57 | 2019-2023 | |
| Coherus Oncology, INC. | $25.42 | 2025 | Loqtorzi |
| Recordati_rare_diseases_inc. | $22.45 | 2025 | Enjaymo |
| Puma Biotechnology, INC. | $18.73 | 2024 | |
| Adc Therapeutics America, INC. | $17.78 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $17.38 | 2019 | |
| Servier Pharmaceuticals LLC | $16.24 | 2024 | |
| Secura Bio, INC. | $16.23 | 2020 | |
| Myovant Sciences INC. | $16.17 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.69 | 2023 | Amvuttra |
| Mirati Therapeutics, INC. | $15.36 | 2023 | Krazati |
| Clovis Oncology, INC. | $12.48 | 2019 | |
| Sirtex Medical INC | $11.91 | 2019 | |
| Janssen Scientific Affairs, LLC | $10.03 | 2025 | Talvey, Tecvayli, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.